Format

Send to

Choose Destination
Pharmacol Ther. 2014 Aug;143(2):246-52. doi: 10.1016/j.pharmthera.2014.03.004. Epub 2014 Mar 19.

Induced pluripotent stem cell-derived cardiomyocytes for drug development and toxicity testing.

Author information

1
Klinikum rechts der Isar - Technische Universität München, I. Medical Department - Cardiology, Ismaninger Strasse 22, 81675 Munich, Germany.
2
Klinikum rechts der Isar - Technische Universität München, I. Medical Department - Cardiology, Ismaninger Strasse 22, 81675 Munich, Germany; DZHK (German Centre for Cardiovascular Research) - Partner Site, Munich Heart Alliance, Munich, Germany.
3
Klinikum rechts der Isar - Technische Universität München, I. Medical Department - Cardiology, Ismaninger Strasse 22, 81675 Munich, Germany; DZHK (German Centre for Cardiovascular Research) - Partner Site, Munich Heart Alliance, Munich, Germany. Electronic address: amoretti@mytum.de.

Abstract

Induced pluripotent stem cell (iPSC) technology is creating exciting new opportunities for cardiovascular research by providing platforms to study the mechanisms of disease pathogenesis that could lead to new therapies or reveal drug sensitivities. In this review, the potential usefulness of iPSC-derived cardiomyocytes in drug development as well as in drug toxicity testing is discussed, with a focus on the achievements that have been already made in this regard. Moreover, the crucial steps that have to be taken before this technology can be broadly used in drug discovery and toxicology assessments are highlighted.

KEYWORDS:

Drug screening; Drug toxicity; High-throughput screening; QT prolongation; iPSC

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center